Steamed Ginseng Berry Powder Ameliorates Skeletal Muscle Atrophy via Myogenic Effects
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Sarcopenia is an age-related loss of muscle mass and function for which there is no approved pharmacological treatment. We tested direct efficacy by evaluating grip strength improvement in a sarcopenia mouse model rather than drug screening, which inhibits specific molecular mechanisms. Various physiological functions of ginseng berries are beneficial to the human body. The present study aimed to evaluate the efficacy and safety of steamed ginseng berry powder (SGBP). SGBP administration increased myotube diameter and suppressed the mRNA expression of sarcopeniainducing molecules. SGBP also reduced the levels of inflammatory transcription factors and cytokines that are known to induce sarcopenia. Oral administration of SGBP improved muscle mass and physical performance in a mouse model of sarcopenia. In summary, our data suggest that SGBP is a novel therapeutic candidate for the amelioration of muscle weakness, including sarcopenia.
Abstract
Sarcopenia is an age-related loss of muscle mass and function for which there is no approved pharmacological treatment. We tested direct efficacy by evaluating grip strength improvement in a sarcopenia mouse model rather than drug screening, which inhibits specific molecular mechanisms. Various physiological functions of ginseng berries are beneficial to the human body. The present study aimed to evaluate the efficacy and safety of steamed ginseng berry powder (SGBP). SGBP administration increased myotube diameter and suppressed the mRNA expression of sarcopeniainducing molecules. SGBP also reduced the levels of inflammatory transcription factors and cytokines that are known to induce sarcopenia. Oral administration of SGBP improved muscle mass and physical performance in a mouse model of sarcopenia. In summary, our data suggest that SGBP is a novel therapeutic candidate for the amelioration of muscle weakness, including sarcopenia.
참고문헌 (30)
- Frontera WR, "Skeletal muscle : a brief review of structure and function", Calcif. Tissue Int, 96, pp.183~195 (2015)
- Moorthi RN, "Clinical relevance of sarcopenia in chronic kidney disease", Curr. Opin. Nephrol. Hypertens, 26, pp.219~228 (2017)
- Relaix F, "A Pax3", Pax7-dependent population of skeletal muscle progenitor cells, 2005, pp.435, 948~953
- Evans WJ, "Skeletal muscle loss : cachexia, sarcopenia, and inactivity", Am. J. Clin. Nutr, 91, pp.1123S~1127S (2010)
- Serres I, "Impaired skeletal muscle endurance related to physical inactivity and altered lung function in COPD patients", Chest, 113, pp.900~905 (1998)
- Schakman O, "Glucocorticoid-induced skeletal muscle atrophy", Int. J. Biochem. Cell Biol, 45, pp.2163~2172 (2013)
- Thomas DR, "Loss of skeletal muscle mass in aging : examining the relationship of starvation, sarcopenia and cachexia", Clin. Nutr, 26, pp.389~399 (2007)
- Millward DJ, "The relative importance of muscle protein synthesis and breakdown in the regulation of muscle mass", Biochem. J, 156, pp.185~188 (1976)
- Bodine SC, "Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx", atrogin-1, 2014, pp.307, E469~E484
- Sandri M, "Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy", Cell, 117, pp.399~412 (2004)
- Stitt TN, "Mol", Cell, 14, pp.395~403 (2004)
- Choi J, "MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes", Proc. Natl. Acad. Sci. USA, 87, pp.7988~7992 (1990)
- Weintraub H, "Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD", Proc. Natl. Acad. Sci. USA, 86, pp.5434~5438 (1989)
- Jaynes JB, "The muscle creatine kinase gene is regulated by multiple upstream elements, including a muscle-specific enhancer", Mol. Cell. Biol, 8, pp.62~70 (1988)
- Miller JB, "Myogenic programs of mouse muscle cell lines : expression of myosin heavy chain isoforms, MyoD1, and myogenin", J. Cell Biol, 111, pp.1149~1159 (1990)
- Spate U, "Proinflammatory cytokines and skeletal muscle", Curr. Opin. Clin. Nutr. Metab. Care, 7, pp.265~269 (2004)
- Kiefer D, "Panax ginseng", Am. Fam. Physician, 68, pp.1539~1542 (2003)
- Leung KW, "Pharmacology of ginsenosides : a literature review", Chin. Med, 5, pp.20~ (2010)
- Kim YJ, "Efficient thermal deglycosylation of ginsenoside Rd and its contribution to the improved anticancer activity of ginseng", J. Agric. Food Chem, 61, pp.9185~9191 (2013)
- Bonaldo P, "Cellular and molecular mechanisms of muscle atrophy", Dis. Model. Mech, 6, pp.25~39 (2013)
- d'Albis A, "Regeneration after cardiotoxin injury of innervated and denervated slow and fast muscles of mammals", Myosin isoform analysis. Eur. J. Biochem, 174, pp.103~110 (1988)
- Zammit PS, "Function of the myogenic regulatory factors Myf5, MyoD, Myogenin and MRF4 in skeletal muscle, satellite cells and regenerative myogenesis", Semin. Cell Dev Biol, 72, pp.19~32 (2017)
- Gumucio JP, "Atrogin-1, MuRF-1, and sarcopenia", Endocrine, 43, pp.12~21 (2013)
- Morley JE, "Sarcopenia", J. Lab. Clin. Med, 137, pp.231~243 (2001)
- Adams V, "Induction of MuRF1 is essential for TNF-alpha-induced loss of muscle function in mice", J. Mol. Biol, 384, pp.48~59 (2008)
- Espat NJ, "Ciliary neurotrophic factor is catabolic and shares with IL-6 the capacity to induce an acute phase response", Am. J. Physiol, 271, pp.R185~R190 (1996)
- Baltgalvis KA, "Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc(Min", +)mouse, 2009, pp.457, 989~1001
- Ryu JS, "The bioavailability of red ginseng extract fermented by Phellinus linteus", J. Ginseng Res, 37, pp.108~116 (2013)
- Gu Y, "Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs", Food Chem. Toxicol, 47, pp.2257~2268 (2009)
- Liu H, "Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats", Drug Metab. Dispos, 37, pp.2290~2298 (2009)